Clinical outcomes with bioabsorbable polymer- Versus durable polymer-based drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis

Journal of the American College of Cardiology

Volumn 63, Issue 4, 2014, Pages 299-307

  Palmerini, Tullio ^a   Biondi Zoccai, Giuseppe ^b   Della Riva, Diego ^a   Mariani, Andrea ^a   Sabaté, Manel ^c   Smits, Pieter C ^d   Kaiser, Christoph ^e   D'Ascenzo, Fabrizio ^f   Frati, Giacomo ^b,g   Mancone, Massimo ^b   Genereux, Philippe ^h,i   Stone, Gregg W ^h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d Maasstad Hospital Rotterdam   (Netherlands)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY OF TURIN   (Italy)

^g IRCCS NEUROMED   (Italy)

^h NewYork Presbyterian Hospital   (United States)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

bare metal stent(s); drug eluting stent(s); meta analysis; stent thrombosis

Indexed keywords

BIOABSORBABLE POLYMER; BIOPOLYMER; CHROMIUM; COBALT; DURABLE POLYMER; EVEROLIMUS; PACLITAXEL; PROMUS; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS; POLYMER;

ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; BIOLIMUS ELUTING STENT; CARDIOVASCULAR STENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RELEASE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE OUTCOME; BIOCOMPATIBILITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COBALT CHROMIUM EVEROLIMUS ELUTING STENT; DEVICE SAFETY; DEVICE THERAPY; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; ZOTAROLIMUS ELUTING STENT;

BARE-METAL STENT(S); BES; BIOABSORBABLE POLYMERS; BIOLIMUS-ELUTING STENT(S); BP; CI; COBALT-CHROMIUM EVEROLIMUS-ELUTING STENT(S); COCR-EES; CREDIBLE INTERVAL; DP; DRUG-ELUTING STENT(S); DURABLE POLYMERS; META-ANALYSIS; ODDS RATIO; OR; PACLITAXEL-ELUTING STENT(S); PC-ZES; PES; PHOSPHORYLCHOLINE-BASED ZOTAROLIMUS-ELUTING STENT(S); PLATINUM CHROMIUM EVEROLIMUS-ELUTING STENT(S); PTCR-EES; RANDOMIZED CONTROLLED TRIAL; RCT; SES; SIROLIMUS-ELUTING STENT(S); ST; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATIONS; TVR;

CARDIOVASCULAR AGENTS; CHROMIUM ALLOYS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; POLYMERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; STENTS;

EID: 84893195179     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.061     Document Type: Article

References (26)

1. J.W. Moses, M.B. Leon, and J.J. Popma et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
2. G.W. Stone, A.J. Lansky, and S.J. Pocock et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction N Engl J Med 360 2009 1946 1959
3. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455 discussion 1455 (Pubitemid 46648381)
4. M. Joner, A.V. Finn, and A. Farb et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
5. R. Virmani, G. Guagliumi, and A. Farb et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705 (Pubitemid 38222887)
6. L. Raber, H. Kelbaek, and M. Ostojic et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
7. G.G. Stefanini, R.A. Byrne, and P.W. Serruys et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
8. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
9. P.C. Smits, S. Hofma, and M. Togni et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial Lancet 381 2013 651 660
10. F. Song, I. Harvey, and R. Lilford Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions J Clin Epidemiol 61 2008 455 463 (Pubitemid 351446184)
11. S. Bangalore, S. Kumar, and M. Fusaro et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
12. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
13. A. Liberati, D.G. Altman, and J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
14. E.H. Christiansen, L.O. Jensen, and P. Thayssen et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial Lancet 381 2013 661 669
15. S. Windecker, P.W. Serruys, and S. Wandel et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
16. I.K. De Scheerder, K.L. Wilczek, and E.V. Verbeken et al. Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries Cardiovasc Intervent Radiol 18 1995 227 232
17. W.J. van der Giessen, A.M. Lincoff, and R.S. Schwartz et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 1996 1690 1697 (Pubitemid 26320276)
18. J.A. Chinn, J.A. Sauter, and R.E. Phillips Jr. et al. Blood and tissue compatibility of modified polyester: thrombosis, inflammation, and healing J Biomed Mater Res 39 1998 130 140 (Pubitemid 128751765)
19. T. Liu, W. Lin, L. Huang, S. Chen, and M. Yang Surface characteristics and hemocompatibility of PAN/PVDF blend membranes Polym Adv Technol 16 2005 413 419 (Pubitemid 40707112)
20. K. Kolandaivelu, R. Swaminathan, and W.J. Gibson et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
21. J. Daemen, P. Wenaweser, and K. Tsuchida et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
22. T. Palmerini, G. Dangas, and R. Mehran et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial Circ Cardiovasc Interv 4 2011 577 584
23. I.T. Meredith, S. Verheye, and C.L. Dubois et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent J Am Coll Cardiol 59 2012 1362 1370
24. G.G. Stefanini, B. Kalesan, and P.W. Serruys et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
25. I. Bossi, C. Klersy, and A.J. Black et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty J Am Coll Cardiol 35 2000 1569 1576 (Pubitemid 30307502)
26. G.W. Stone, S.G. Ellis, and A. Colombo et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 115 2007 2842 2847 (Pubitemid 46869671)